Trial · NCT04216693
Digoxin for Patients With Non-alcoholic Steatohepatitis (NASH)
NCT04216693, Phase 2, Withdrawn, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Digoxin for Patients With Non-alcoholic Steatohepatitis (NASH). Trials, record NCT04216693. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04216693
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Digoxin for Patients With Non-alcoholic Steatohepatitis (NASH)
- NCT number
- NCT04216693
- Status
- Withdrawn
- Phases
- Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- Digoxin tablet, Placebo
- First posted
- 2020-01-03
- Last updated
- 2023-02-22
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Two point change in histological NAFLD activity score (NAS) | Baseline, 24 weeks | Non-alcoholic fatty liver disease score (NAS) is a histological classification to assess the severity of liver steatosis, lobular inflammation and ballooning in the liver biopsy, which ranges from 0-8 with the increase in number representing a worse outcome. Therefore, the efficacy improvement was to be at least 2 points in lowering the score. |
| Primary | Proportion of subjects with at least a 30% change in % steatosis relative to screening | Baseline, 24 weeks | Liver steatosis is graded based on the percentage of fat within the hepatocytes: grade 0 (healthy, \<5%), grade 1 (mild, 5%-33%), grade 2 (moderate, 34%-66%), and grade 3 (severe, \>66%). the efficacy improvement was to be proportion of subjects with at least a 30% decrease in % steatosis relative to screening. |
| Secondary | Change in the mean concentration of serum aspartate aminotransferase (AST) | 0, 2, 4, 6, 11, 24 weeks | |
| Secondary | Change in the mean concentration of serum alanine aminotransferase (ALT) | 0, 2, 4, 6, 11, 24 weeks | |
| Secondary | Change in liver histological fibrosis staging | Baseline, 24 weeks | Fibrosis staging was measured as following criteria: 0=none, 1=perisinusoidal or periportal fibrosis, 2=perisinusoidal and portal/periportal fibrosis, 3=bridging fibrosis, and 4=cirrhosis.the definition of fibrosis stages improvement requires at least one stage. |
| Other | Change in the mean concentration of serum inflammation markers | 0, 2, 4, 6, 11, 24 weeks | Change from baseline in Interleukin (IL)-6, C-reactive Protein (CRP). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 29414684 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04216693
GET https://conductscience.org/api/trials/v1/NCT04216693/registered